BIIB Stock Alert: Biogen’s $5.6B Apellis Deal – Buy or Sell?

BIIB stock is facing a massive shift today as Biogen officially announces a $5.6 billion acquisition of Apellis Pharmaceuticals. While this move strengthens their rare disease portfolio, investors are reacting to the high price tag and the continued decline of legacy MS drugs.

In this deep-dive analysis, we break down the latest 2026 financial guidance, the impact of the new SPINRAZA® high-dose FDA approval, and whether the current dip is a "generational buying opportunity" or a "falling knife."

Queries:
Biogen stock price today, BIIB earnings report 2026, Biogen Apellis acquisition news, BIIB technical analysis, Biogen dividend yield, best biotech stocks to buy now 2026, BIIB stock price prediction, LEQEMBI sales growth, Biogen vs Amgen stock comparison, BIIB short interest data.

Key Chapters:
00:00 BIIB Stock Price Action & Market Reaction
01:30 The $5.6B Apellis Deal: Breakdown & Risks
03:45 Financial Deep Dive: Revenue vs. New FDA Approvals
06:20 Technical Analysis: Support Levels & RSI Signals
08:15 Final Verdict: Short-term Weakness vs. Long-term Growth

#BIIB #Biogen #StockMarket #BiotechStocks #Investing #StockAnalysis #BreakingNews

Видео BIIB Stock Alert: Biogen’s $5.6B Apellis Deal – Buy or Sell? канала Stock US Radar